Try our beta test site
13 studies found for:    Tysabri | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Tysabri Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: natalizumab
2 Recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
3 Recruiting Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
Condition: Multiple Sclerosis
4 Recruiting Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Condition: Acute Graft Versus Host Disease
Interventions: Drug: natalizumab;   Drug: steroids
5 Recruiting Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Radiation: Diffusion Magnetic Resonance Imaging at 6 months
6 Recruiting Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
7 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
8 Recruiting Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: biological samples and clinical data
9 Recruiting Methylprednisolone During the Switch Between Natalizumab and Fingolimod
Condition: Multiple Sclerosis
Interventions: Drug: Methylprednisolone;   Drug: Placebo;   Drug: natalizumab (NTZ);   Drug: fingolimob (FTY)
10 Recruiting Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Other: mitoxantrone - immunomodulator;   Other: natalizumab
11 Recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
12 Recruiting Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Condition: Multiple Sclerosis
13 Recruiting Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Condition: Multiple Sclerosis
Interventions: Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug

Study has passed its completion date and status has not been verified in more than two years.